Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zymeworks Inc ZYME

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.


NDAQ:ZYME - Post by User

Post by 4Justiceon Jan 12, 2022 4:51pm
198 Views
Post# 34310272

GALBRAITH THE STORY BEHIND

GALBRAITH THE STORY BEHINDWHAT REALLY HAPPENED ?

I the last three years Zymeworks raised close to $600millions.

The company has no revenue from operation and a $170 millions burn rate a year without solid scientific results.

82% of the money comes from big VC's. They have losted close to 70% of their investment by now.

WHAT DO YOU YOU THINK THEY DID ?

They called the CFO, Neil Klompas, and told him to move something if he doesn't want to see the pipeline closed. Simple as that.

Klompas called a meeting with the board and suggested as a brilliant solution...a new CFO, leader in the biothechnology industry. He knows the guy, he sat with him on the board of Liminal, the wreck of Prometic. Galbraith was the former CEO expected to be the salvator.

Now do your own DD on this guy and his skill to become a game changer.

VC,s should talk together if they have a concern about their clients money.

As I'm concerned Galbraith is a kind of "chicken exit"

Just my thought after lot of reading.
<< Previous
Bullboard Posts
Next >>